Ecrins Therapeutics (project sponsor), in collaboration with Oncovet Clinical Research (a veterinary clinic based in Lille), the Centre Léon Bérard, and the Institut de Génétique et Développement de Rennes launched the Dog to Man project. It is funded in the framework of the 19th call for projects of the FUI (Unique Interministerial Fund).
The selection process involved screening and approval by Lyonbiopôle’s experts, shortly followed by National experts. The goal of the Dog to Man project is to develop an innovative product (ET-D5) aimed at treating sarcomas through a translational clinical study from dog to man.
Sarcomas are rare cancers (accounting for only 1% of all diagnosed cancers), but they are more frequent in children, representing 15% of pediatric cancers. Their treatment involves surgery – often accompanied by radiotherapy and/or adjuvant chemotherapy, especially in later stages of the disease. Aside from certain sarcomas for which targeted treatments are effective, vital prognosis remains pessimistic (survival rates at 5 years is approx. 45-65%). For this reason, there is real need for new and effective sarcoma therapies. It is in hopes of filling that need that Ecrins Therapeutics has geared its lead compound (ET-D5) towards this field.
Sarcomas are relatively frequent in dogs: accounting for up to 15% of all tumors. That is why it makes perfect sense to recruit canine patients first, and should the first-in-dog clinical trial prove successful, to move on to first-in-human clinical study.
To increase the chances of success for our clinical trials, we have opted for an original approach by first treating dogs diagnosed with sarcomas. Comparative oncology studies have unequivocally shown that certain dog cancers are excellent models for studying the corresponding tumors in humans. In this project, the results of the clinical trial conducted in dogs will be transposed to humans in order to increase the chance of success of the product on human sarcomas. Furthermore, the data obtained from that trial will allow us to more rapidly develop a veterinary drug for the treatment of dog sarcomas.
This project is based on the complementary expertise of four partners specialized in veterinary oncology, cancer genetics, clinical monitoring, and in pre-clinical development of therapeutic molecules and biomarkers.
In the frame of Dog to Man, Ecrins Therapeutics is partially funded by Grenoble Alpes Métropole and the Département de l’Isère.